Research programme: NNR modulators - GlaxoSmithKline/Targacept

Drug Profile

Research programme: NNR modulators - GlaxoSmithKline/Targacept

Latest Information Update: 23 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targacept
  • Class Small molecules
  • Mechanism of Action Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Drug abuse; Obesity; Pain; Parkinson's disease; Smoking withdrawal

Most Recent Events

  • 04 Mar 2011 The strategic alliance between Targacept and GlaxoSmithKline terminates, effective May 2011
  • 06 May 2008 Targacept selects a lead compound for development in smoking cessation triggering a milestone payment from GlaxoSmithKline
  • 11 Dec 2007 A lead candidate from this research programme, TC 6499, enters clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top